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Abstract
Background: Understanding participation in a prospective study is crucial to maintaining and
improving retention rates. In 1990–92, following attempted blood donation at five blood centers,
we enrolled 155 HTLV-I, 387 HTLV-II and 799 HTLV seronegative persons in a long-term
prospective cohort.
Methods: Health questionnaires and physical exams were administered at enrollment and 2-year
intervals through 2004. To examine factors influencing attendance at study visits of the cohort
participants we calculated odds ratios (ORs) with generalized estimated equations (GEE) to analyze
fixed and time-varying predictors of study visit participation.
Results: There were significant independent associations between better visit attendance and
female gender (OR = 1.31), graduate education (OR = 1.86) and income > $75,000 (OR = 2.68).
Participants at two centers (OR = 0.47, 0.67) and of Black race/ethnicity (OR = 0.61) were less
likely to continue. Higher subject reimbursement for interview was associated with better visit
attendance (OR = 1.84 for $25 vs. $10). None of the health related variables (HTLV status,
perceived health status and referral to specialty diagnostic exam for potential adverse health
outcomes) significantly affected participation after controlling for demographic variables.
Conclusion: Increasing and maintaining participation by minority and lower socioeconomic status
participants is an ongoing challenge in the study of chronic disease outcomes. Future studies should
include methods to evaluate attrition and retention, in addition to primary study outcomes,
including qualitative analysis of reasons for participation or withdrawal.
Background
Understanding participation in a prospective study is cru-
cial to maintaining and improving retention rates [1,2]. A
high participant loss rate will impact the ability to draw
valid conclusions. This is particularly relevant in longitu-
dinal studies where loss of data points within or between
visits can distort the relationships between measurements
[3,4]. Many strong predictors of attrition, such as health
problems and socioeconomic factors [5], race/ethnicity
[6], and substance abuse [7] have been explored in efforts
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to develop strategies to maintain participation in a long
term cohort study. Most studies evaluate retention by
employing a survival approach, looking at the time to loss
to follow-up; some have explored positive and negative
predictors of retention in long-term prospective studies
using mixed model statistical techniques [8]. But few have
examined drop-out of study participants followed by
return after missing at least one visit. Although newer sta-
tistical techniques allow analysis of data with missing data
points, minimization of attrition still remains important
for drawing valid research conclusions [9].
The purpose of this paper was to examine factors influenc-
ing the continued or renewed participation of subjects in
a prospective longitudinal cohort study of human T-cell
lymphotropic virus (HTLV) outcomes. By analyzing the
large HTLV Outcomes Study (HOST) data set, we had the
opportunity to investigate some uncommon but possible
reasons for long-term study participation. The HTLV pos-
itive donors, with matched controls, followed in HOST
since the early 1990s, permitted the examination of three
research questions: first, does diagnosis with a relatively
obscure virus in healthy adults impact study retention;
second, does poorer health status influence participants to
continue in a study, and third, does referral for specialty
physician diagnostic examination, an indication of possi-
ble development of HTLV-associated disease or other
adverse health outcome, contribute to long-term study
enrollment. Our hypothesis was that healthy persons
diagnosed with HTLV would be more likely to continue in
a longitudinal study that included regular health assess-
ments compared to HTLV negative controls. Further, we
hypothesized that changes toward poorer health status
regardless of HTLV status would increase the likelihood of
staying in or reengaging in the study.
Methods
Sample
Beginning in 1990 through 1992, 155 HTLV-I seroposi-
tive, 387 HTLV-II seropositive and 799 seronegative par-
ticipants were enrolled from populations of blood donors
from five sites across the United States. Participants were
aged 18 and older, testing either positive or negative for
HTLV at the time of attempted donation. HOST data have
been the source of many publications on the transmis-
sion, natural history and health outcomes of HTLV infec-
tion [10-15]. HOST is an extension of the cohort enrolled
previously under the Retrovirus Epidemiology Study
(REDS) and the details of HOST study design have been
described elsewhere [16].
To improve the comparability of the groups, seronegative
subjects were matched to HTLV seropositive subjects by
age (5 year groups), sex, race/ethnicity, type of blood
donation (whole blood, autologous or platelet pheresis)
and blood center. A ratio of 1.5 seronegatives to HTLV
seropositives was attempted, anticipating lower follow-up
success with seronegative subjects. All participants were
HIV seronegative. The HOST cohort included some sexual
partners of HTLV seropositive donors, but they are
excluded from analysis in this paper.
Setting
HOST is a multi-center, longitudinal prospective cohort
study of the health effects of infection with HTLV-I and
HTLV-II occurring at five blood banks in United States cit-
ies. The five clinical and data collection sites include three
American Red Cross (ARC) blood services centers: Chesa-
peake/Potomac (Washington/Baltimore), Southeastern
Michigan (Detroit), and Southern California (Los Ange-
les), as well as two independent blood centers: Blood
Centers of the Pacific in San Francisco, California and the
Oklahoma Blood Institute in Oklahoma City, Oklahoma.
Testing for HTLV was routinely done at the time of blood
donation, and donors found to be seropositive were per-
manently deferred from blood donation prior to enroll-
ment. Seropositive persons are not usually ill, as there is
only a 1–2% risk of progressing to either of the two recog-
nized HTLV related diseases: adult T-cell leukemia (ATL)
and HTLV-associated myelopathy (HAM) [17].
Procedures
Following enrollment and baseline data collection in
1990–92, participants have been contacted every two
years to complete the three activities that comprise each
visit: a health questionnaire, a basic neurologic exam, and
phlebotomy for complete blood count and storage of
specimens in the HOST biorepository. All activities and
procedures were identical for seropostive and seronega-
tive participants. Nurse counselors at each site were
trained and monitored to perform all study activities in a
standardized manner, but there was staff turnover during
follow-up. The structured interview questions were asked
by the study nurse and entered into a questionnaire book-
let as the participant answered each question. Attempts
were made to see all participants in person, but telephone
interviews were accepted from participants who had
moved out of state or who refused an in-person visit. An
exception was the fourth study visit. Due to decreased
resources, the fourth visit had a protocol modification
which differed from the other visits. It consisted of an
abbreviated health questionnaire completed by mail or
telephone, no basic neurologic examination, and remote
phlebotomy with the blood sample sent by courier to the
central laboratory. The study reverted back to the original
protocol when resources were restored for visits 5 and 6.
During each visit, an effort was made to limit the number
of participants lost to follow-up by updating subject infor-
mation for possible changes of name, address or tele-
phone number. Participants consented to allow study
personnel to search telephone directory assistance, theBMC Medical Research Methodology 2009, 9:19 http://www.biomedcentral.com/1471-2288/9/19
Page 3 of 10
(page number not for citation purposes)
U.S. Postal Service forwarding service, public use data-
bases, and credit bureau records if their previous informa-
tion had changed between visits. Additionally, at each
visit, participants were asked to designate a relative or
friend who could be contacted to provide updated contact
information or knowledge of the subject's death. In cases
where the participant and designated contact person were
no longer valid sources of information, a professional
tracing expert was assigned to the participant with the pur-
pose of discovering new contact information.
The health questionnaire, neurologic exam and phlebot-
omy were developed to screen for medical conditions or
disease outcomes which might be associated with HTLV-I
or HTLV-II, including ATL or HAM. Study clinicians devel-
oped an algorithm to identify abnormal responses in the
health questionnaire, neurologic exam or phlebotomy
results. A computer program was written to use the algo-
rithm to screen all participant data (health questionnaire,
basic neurologic exam, complete blood count and medi-
cal records) and identify/flag participants whose data were
suggestive of clinical outcomes. A panel of three medical
physicians with expertise in HTLV clinical and hemato-
logic presentation met at regular intervals during each
visit. The panel was blinded to participant serostatus and
made decisions for participant referral to the local study
physician and/or specialty physician for further diagnostic
examinations in a uniform fashion.
Data
Dependent Variable
The outcome of interest for this analysis is the attendance
of study participants at each of the visits 2, 3, 5 and 6, fol-
lowing enrollment in the baseline visit 1. Data for visit 4
were excluded because of different procedures for that
visit (see above). Study visit participation was defined as
active if a participant completed at least a study health
questionnaire either in person or by telephone, whether
or not he or she completed the screening physical exam
and phlebotomy.
Independent Variables
Our independent variables were related to health status in
a natural history study. One was HTLV status (HTLV-I,
HTLV-II or seronegative) measured at baseline. Perceived
health status, measured by a five item Likert scale from
excellent to poor, was measured at each visit. The third
independent variable was referral to a specialty physician
diagnostic examination, also determined at each visit. In
addition to the main independent variables, another
time-varying variable measured at each visit was reim-
bursement for interview, which changed from $10 to $25
for visits 4, 5 and 6.
Covariates
Fixed covariates measured at baseline were gender, age,
race/ethnicity, education, annual income, ever use of
injection drugs and study site. Race/ethnicity was
recorded in detail (16 specific origins corresponding to
risk groups for HTLV infection) but was collapsed to five
for the analysis (White, Black, Hispanic, Asian and other).
Educational achievement was collapsed from six catego-
ries (8th grade or less; 9th–12th grade but no diploma; high
school graduate or equivalent, such as GED; some college
or technical school; bachelor's degree; master's or profes-
sional degree) to four (high school or less; some college;
bachelor's degree; master's or professional degree).
Income was collapsed from seven categories (<$10,000;
$10,000 to 19,999; $20,000 to 29,000; $30,000 to
39,999; $40,000 to 49,999; $50,000 to 74,999 and
$75,000 or more) to five (< $10,000; $10,000 to 29,000;
$30,000 to 49,999; $50,000 to 74,999 and > $75,000).
Analysis
We first described the sample on baseline characteristics
by HTLV status using chi-square tests comparing the per-
cent in each category across HTLV status. In our initial
analysis, we first categorized participants as taking part in
visit 1 only (baseline only), in visit 1 and at least one other
visit (some follow-up) or in all visits (all follow-up) by
chi-square tests to compare proportions in each category.
We then used multivariate Generalized Estimating Equation
(GEE) analysis to test the relationship between attendance at
a study visit after baseline enrollment at visit 1 and inde-
pendent variables over time. The model included the fixed
(HTLV status, gender, age, race/ethnicity, education, income,
ever drug use and site) and time-varying (health status at pre-
vious visit, referral to a specialty physician diagnostic exami-
nation at previous visit and reimbursement at previous visit)
variables. Variables were then sequentially removed, starting
with the least statistically significant. We forced two variables
(HTLV status and referral for further exam) into the final
model for plausibility: our hypothesis is that they were asso-
ciated with participation, although they were not statistically
significant in our adjusted model. Time was entered in the
model as visit, and attendance at each visit was used to pre-
dict attendance at the following visit. GEE analysis does not
require a balanced design (i.e., observations at all measure-
ments for each participant), and it accommodates correlated
errors due to repeated measures. We used the binomial logit
function to estimate the likelihood of participation and to
present the results of these tests in the form of adjusted odds
ratios (OR) with 95% confidence intervals (CI). All analyses
were done with SAS, version 9.0 (SAS Institute, Inc., Cary,
NC).
Results
The characteristics of the 1341 participants at baseline are
shown, by HTLV status, in Table 1. HTLV-I blood donors
were more likely to be Black and HTLV-II donors to be
Hispanic, and both HTLV seropositive groups were
observed to have lower education and lower annual
income than HTLV seronegative donors.BMC Medical Research Methodology 2009, 9:19 http://www.biomedcentral.com/1471-2288/9/19
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After recruitment and baseline data collection in visit 1,
88 (7%) participants were lost to follow-up and com-
pleted no further interviews or examinations; 51 (14%)
after visit 2, 113 (31%) after visit 3, 84 (23%) after visit 5.
Most of the 366 (27%) participants who dropped out
were lost at the second or third visit. As some participants
rejoined the study, a total of 1020 (76%) participants
completed one or more follow-ups from visit 2 through
visit 6, and 233 (17%) participants completed all visits.
All 1341 participants were seen in person at baseline. Tel-
ephone interviews rather than in-person visits were done
for 3% at visit 2, for 8% at visit 3, for all participants at
visit 4 as described earlier, for 56% at visit 5, and for 40%
at visit 6. Of the 1341 participants enrolled at baseline,
985 participated in visit 6 (73%). Characteristics in bivar-
iate analysis by sociodemographic and health-related var-
iables and study site, by these groupings of participation,
are shown in Table 2.
Overall study participation by site is shown in Figure 1.
Visit 4 had a telephone rather than in-person interview,
and demonstrated considerably lower study participation.
Table 1: Characteristics of the HOST study sample at baseline by HTLV status, 1990–1992
Characteristic (N) HTLV-I
N (%)
N = 155
HTLV-II
N (%)
N = 387
HTLV-Negative
N (%)
N = 799
Total
N (%)
N = 1341
Gender (1341)
Male 44 (28) 102 (26) 257 (32) 403 (30)
Female 111 (72) 285 (74) 542 (68) 938 (70)
Age (1341)
18–29 10 (6) 23 (6) 68 (8) 101 (8)
30–39 31 (20) 157 (41) 241 (30) 429 (32)
40–49 66 (43) 136 (35) 269 (34) 471 (35)
50–59 22 (14) 49 (13) 131 (17) 202 (15)
≥ 60 26 (17) 22 (6) 90 (11) 138 (10)
Race/Ethnicity (1327)
White 59 (39) 138 (36) 309 (39) 506 (38)
Black 61 (40) 124 (32) 243 (31) 428 (32)
Hispanic 9 (6) 104 (27) 152 (19) 265 (20)
Asian 20 (13) 6 (2) 50 (6) 76 (6)
Other 3 (2) 10 (3) 39 (5) 52 (4)
Education (1340)
High school or less 54 (35) 155 (40) 147 (18) 356 (27)
Some college 63 (41) 179 (46) 362 (45) 604 (45)
Bachelor's degree 25 (16) 40 (10) 179 (23) 244 (18)
Master's or professional degree 12 (8) 13 (3) 111 (14) 136 (10)
Annual income (1328)
<$10,000 13 (8) 40 (10) 30 (4) 83 (6)
$10,000–29,999 645 (30) 130 (34) 173 (22) 348 (26)
$30,000–49,999 47 (31) 121 (31) 243 (31) 411 (31)
$50,000–74,999 29 (19) 67 (17) 204 (26) 300 (23)
≥ $75,000 18 (12) 26 (7) 142 (18) 186 (14)
Health status (1341)
Excellent 87 (22) 313 (39) 44 (28) 444 (33)
Very good 129 (33) 329 (41) 42 (27) 500 (37)
Good 118 (30) 139 (17) 54 (35) 311 (23)
Fair & Poor 53 (14) 18 (2) 15 (10) 84 (6)
Ever used injection drugs (1338)
No 152 (99) 294 (76) 788 (99) 1234 (92)
Yes 2 (1) 92 (24) 10 (1) 104 (8)
Site (1341)
Chesapeake 32 (21) 51 (13) 122 (15) 205 (15)
Detroit 32 (21) 39 (10) 102 (13) 173 (13)
Los Angeles 44 (28) 206 (53) 345 (43) 595 (44)
Oklahoma City 16 (10) 23 (6) 74 (9) 113 (8)
San Francisco 31 (20) 68 (18) 156 (20) 255 (19)
Not all subjects answered every question; the number answering each question is listed with each characteristic. Percentages may not add to 100 
because of rounding, and are based on those answering the question.BMC Medical Research Methodology 2009, 9:19 http://www.biomedcentral.com/1471-2288/9/19
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Further, the visit 4 health questionnaire did not include
the perceived health status question. Because of the result-
ing loss of data and statistical power and our interest in
perceived health as a predictor of participation, we exam-
ined GEE results and found no differences in effect sizes
with and without visit 4 data. Table 3 and Figure1 there-
fore present results on study participation excluding visit
4.
Among health-related variables in the bivariate analysis,
HTLV-seronegatives and those with excellent or good
health status were more likely to attend study visits (Table
Table 2: Subject participation by HTLV status and baseline characteristics
Characteristic (N)a Participated in All Follow-up
N (%)
N = 233(17)
Participated in Some Follow-
up
N (%)
N = 1020(76)
Participated in Baseline onlyb
N (%)
N = 88(7)
Total
N (100%)c
N = 1341
P
Viral status (1341) 0.07
HTLV-I 30 (19) 110 (71) 15 (10) 155
HTLV-II 70 (18) 285 (74) 32 (8) 387
HTLV-Negative 133 (17) 625 (78) 41 (5) 799
Gender (1341) 0.15
Male 59 (15) 313 (78) 31 (8) 403
Female 174 (18) 707 (75) 59 (6) 938
Age (1341) 0.25
18–29 15 (15) 77 (76) 9 (9) 101
30–39 74 (17) 320 (75) 35 (8) 429
40–49 92 (20) 351 (74) 31 (6) 471
50–59 28 (14) 165 (81) 10 (5) 202
≥ 60 24 (17) 109 (79) 5 (4) 138
Race/Ethnicity (1330) 0.01
White 80 (16) 402 (79) 24 (5) 506
Black 94 (21) 298 (70) 39 (9) 428
Hispanic 38 (14) 211 (80) 16 (6) 265
Asian 8 (10) 62 (82) 6 (8) 76
Other 11 (21) 37 (71) 4 (8) 52
Education (1340) 0.05
High school or less 70 (20) 252 (71) 34 (9) 356
Some college 103 (17) 465 (77) 37 (6) 604
Bachelor's degree 43 (18) 192 (79) 10 (4) 244
Master's or professional 
degree
17 (12) 112 (82) 7 (5) 136
Annual income (1328) 0.03
<$10,000 11 (13) 62 (75) 10 (12) 83
$10,000–29,999 69 (20) 248 (71) 31 (9) 348
$30,000–49,999 68 (16) 316 (77) 27 (6) 411
$50,000–74,999 50 (17) 236 (77) 14 (5) 300
≥ $75,000 31 (17) 150 (81) 5 (3) 186
Health status (1341) 0.02
Excellent 65 (15) 347 (78) 32 (7) 444
Very good 92 (18) 383 (77) 25 (5) 500
Good 57 (18) 235 (76) 19 (6) 311
Fair & Poor 19 (22) 55 (64) 12 (14) 86
Ever used IV drugs (1338) 0.21
Yes 17 (16) 76 (73) 11 (11) 104
No 216 (18) 942 (76) 76 (6) 1234
Site (1341) <.001
Chesapeake 68 (33) 125 (61) 12 (6) 205
Detroit 27 (16) 129 (75) 17 (9) 173
Los Angeles 59 (10) 501 (84) 35 (6) 595
Oklahoma City 27 (24) 82 (72) 4 (4) 113
San Francisco 52 (20) 183 (72) 20 (8) 255
a Not all subjects answered every question; the number who did is listed with each characteristic. Percents may not add to 100 because of rounding, 
and are based on those answering the question.
bThese subjects provided data at baseline (Visit1) only.
c The total represents all who answered the question.BMC Medical Research Methodology 2009, 9:19 http://www.biomedcentral.com/1471-2288/9/19
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3). However, in multiple regression analysis, neither
health status nor HTLV status was associated with partici-
pation after adjusting for relevant covariates. Referral for
speciality physician diagnostic exam was not a significant
predictor of participation. We examined health status,
which was significant in bivariate analyses but not in the
multivariate model. We found that education accounted
for the apparent association between health status and
visit participation seen in the bivariate model.
Table 3: Predictors of subject visit participation in HOST study by bivariate and multivariate GEE analysis.
Predictor Crude OR
(95% CI)
Pa Adjusted OR
(95% CI)
Pb
Site
Chesapeake 0.72 (0.48, 1.09) 0.12 0.69 (0.45, 1.04) 0.08
Detroit 0.45 (0.30, 0.67) <0.001 0.47 (0.31, 0.71) <0.001
Los Angeles 0.73 (0.52, 1.03) 0.08 0.67 (0.48, 0.94) 0.02
Oklahoma City 0.88 (0.56, 1.40) 0.59 0.75 (0.47, 1.19) 0.22
San Francisco Reference Reference
Phase
Visit 3 vs. Visit 2 0.63 (0.54, 0.73) <0.001 1.34 (1.00, 1.79) 0.05
Visit 5 vs. Visit 3 0.29 (0.24, 0.35) <0.001 0.29 (0.22, 0.39) <0.001
Visit 6 vs. Visit 5 0.28 (0.23,0.33) <0.001 1.38 (0.90, 2.11) 0.14
Reimbursement for interview
$25 vs. $10 1.14 (0.95, 1.47) 0.13 1.84 (1.22, 2.77) 0.004
Gender
Female 1.25 (0.99, 1.57) 0.05 1.31 (1.04, 1.66) 0.02
Male Reference Reference
Age
One year increase 1.00 (0.99, 1.02) 0.69 1.00 (0.99, 1.01) 0.41
Race/Ethnicity
Black 0.51 (0.40, 0.67) <0.001 0.61 (0.47, 0.80) 0.004
Asian 0.74 (0.44, 1.24) 0.25 0.68 (0.42, 1.10) 0.11
Hispanic 0.71 (0.52, 0.96) 0.03 0.76 (0.56, 1.04) 0.09
Other 0.59 (0.35,0.99) 0.05 0.59 (0.36, 0.99) 0.05
White Reference Reference
Education
High school or less Reference Reference
Some college 1.35 (1.05, 1.73) 0.02 1.14 (0.89, 1.47) 0.29
Bachelor's degree 2.01 (1.43, 2.28) <0.001 1.56 (1.09, 2.23) 0.02
Master's or professional degree 2.31 (1.45, 3.67) <0.001 1.86 (1.19, 2.92) 0.01
Annual income
<$10,000 Reference Reference
$10,000–29,999 1.56 (1.04, 2.34) 0.03 1.47 (0.97, 2.28) 0.07
$30,000–49,999 1.74 (1.17, 2.59) 0.01 1.57 (1.04, 2.40) 0.03
$50,000–74,999 2.52 (1.64, 3.88) <0.001 1.96 (1.24, 3.10) 0.004
≥ $75,000 3.73 (2.25, 6.19) <0.001 2.68 (1.58, 4.56) 0.003
Health status in previous Visit
Excellent 1.72 (1.18,2.50) 0.01 1.20 (0.80, 1.81) 0.38
Very good 1.75 (1.22,2.52) 0.003 1.33 (0.91, 1.96) 0.14
Good 1.18 (081,1.72) 0.38 1.12 (0.85, 1.47) 0.14
Fair or Poor Reference Reference
Ever used IV drugs
Yes 1.57(1.08,2.26) 0.02 1.08 (0.83,1.42) 0.55
No Reference Reference
HTLV status
HTLV-I 0.64 (0.46, 0.89) 0.01 1.12 (0.85,1.47) 0.42
HTLV-II 0.70 (0.55, 0.88) 0.003 1.01 (0.70, 1.45) 0.96
HTLV-Negative Reference Reference
Referral for further exam in previous visit
Yes 0.86 (0.68, 1.09) 0.22 1.08 (0.83,1.42) 0.55
No Reference Reference
Note: OR = odds ratio; CI= confidence interval.
abivariate analysis
bmultivariate analysis, controlling for all other values shown in the tableBMC Medical Research Methodology 2009, 9:19 http://www.biomedcentral.com/1471-2288/9/19
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Of the protocol-related variables, higher subject reim-
bursement and study site were statistically significant pre-
dictors of participation at a subsequent visit. When
reimbursement was increased from $10 to $25, partici-
pants were nearly twice as likely to continue (adjusted OR
1.84). As shown by the differences in proportions, partic-
ipation by study site remained significant in the GEE anal-
ysis. In particular, compared to the San Francisco site,
Detroit and Los Angeles were significantly less likely to
participate (adjusted OR 0.47 and 0.67, respectively).
Of the sociodemographic variables examined, there was a
clear trend for socioeconomic status. Those in higher
income categories were increasingly more likely to con-
tinue in the study as compared to those in the lowest
income group, with those reporting $75,000 or more in
annual income 2.68 times as likely to continue as those
making less than $10,000. A similar trend was seen for
increasing education, with those in the highest education
category 1.86 times as likely as those with high school or
less education to participate in study visits. Women were
more likely to participate compared to men (adjusted OR
1.31), and Blacks and "other race" subjects were less likely
to attend study visits as compared to Whites (adjusted OR
0.61 and 0.59, respectively).
Discussion
The main findings of this study were that persons with
higher incomes and more education were more likely to
participate in study visits and men and persons of Black
and other race/ethnicity were less likely to participate.
Contrary to our hypothesis, HTLV seropositivity, poorer
perceived health status, and referral to specialty diagnostic
exam for potential adverse health outcomes did not sig-
nificantly affect participation after controlling for demo-
graphic variables. Specific protocol-related characteristics
did matter: study site and an increase in reimbursement
were positively associated with participation.
Retention rates overall have remained high in this 12 year
study of blood donors, 73% through visit 6. By virtue of
selection criteria, blood donors are generally healthier
than the general population. The diagnosis of a viral infec-
tion, with serious albeit rare consequences, is an unex-
pected consequence of blood donation. We hypothesized
that being seropositive for HLTV, having poorer perceived
health status, and referral for further physician examina-
tion because of possible HTLV-related disease would be
associated with higher rates of overall participation and
re-engagement in subsequent visits. Our data did not sup-
port these hypotheses: HTLV positive status, perceived
health status, and referral for specialty physician diagnos-
tic examination made no difference in retention or reen-
gagement of participants. This inability to reject the null
hypothesis is reassuring for the HOST study's scientific
validity. Loss to follow-up related to HTLV seropositivity
and the presence of adverse health outcomes, whether
perceived or as a result of changes in objective health
measures, could be an important source of bias in this
longitudinal study.
Instead, as previously reported in the literature, demo-
graphic factors were important predictors of retention in
this cohort. Males, those with lower education and lower
income, and persons of color were less likely to participate
in study visits. There is controversy about the effect of gen-
der on study participation. Some studies indicate women
have been shown to be more likely to consent to study
participation [18] and continue in studies over time [19],
others say there is no difference in participation by gender
[20].
What is novel in this research is that the health status of
the participants did not appear to affect visit participation.
These findings are difficult to compare with other studies
because of the inherent difference of these essentially
healthy participants with a diagnosis as positive with a
virus yet not ill, compared to participants in longitudinal
studies of chronic illness. Poor health is usually predictive
of dropping out of longitudinal studies [5,21,22].
Increasing and maintaining participation by underrepre-
sented groups, who are likely to be in lower socioeco-
nomic strata as well, is an ongoing challenge for
researchers wanting to characterize health and disease for
the general population [23-26]. While studies have shown
that blood donors as a group have higher socioeconomic
status [27], the persistent and independent influence of
Number of subjects submitting health questionnaires at each  of 5 visits (1990–1992 through 2002–2004) by study site Figure 1
Number of subjects submitting health questionnaires 
at each of 5 visits (1990–1992 through 2002–2004) by 
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race/ethnicity, education and income demonstrates the
continued and urgent need to develop and test strategies
to encourage participation by under-represented groups.
In addition to well known sociodemographic factors,
notable differences in the protocol and its implementa-
tion were important in study participation. As others have
shown [28] the increase of monetary reimbursement
(from $10 in visit 3 to $25 in visit 4) was positively asso-
ciated with study participation. The most dramatic change
in participation was seen in visit 4 when interviews were
done by telephone or mail and phlebotomy was done
remotely, instead of in-person interviews and phlebot-
omy by the study nurse. The modified approach resulted
in profound decreases in participation at all centers and
despite the increase in reimbursement, so for subsequent
visits the study resumed in-person methods. Moreover,
differences by site despite consistency in training and pro-
tocol management may have represented subtle differ-
ences in personnel and in implementation of the
protocol. For example, the Los Angeles site reported that
subjects moved often and required intensive tracing
efforts, and that urban sprawl and the large, traffic-con-
gested metropolitan area was cited by many subjects as a
reason to drop out. Anecdotally, frequent changes in
study nurses at some centers probably disrupted rapport
essential to maintaining retention. These protocol and
logistical observations, while consistent with common
sense, remain crucial to the successful implementation of
future prospective studies.
Strengths of this analysis are that the data concerned five
different blood centers and a long follow-up period.
HOST follows a uniform, well funded study protocol with
a data coordinating center. The overall retention rate was
high, allowing better measurement of differences among
study groups. Limitations include the telephone follow-
up in visit 4, which was addressed by excluding those
data. In addition, few variables were collected specifically
for the analysis of study participation. As is often the case,
studies of retention are secondary analyses, peripheral to
the primary research aim, and often do not have the depth
or richness of data to examine the more subjective aspects
of retention.
Conclusion
In future research, investigators may wish to study various
strategies to minimize participant attrition. These have
been categorized by others into three areas: competence,
dedication and standardized training; communication
and collaborative effort between participant and
researcher; and expressions of appreciation to participants
[29-33]. For future longitudinal, natural history studies,
researchers should consider the collection of data specifi-
cally related to study participation, including characteris-
tics of study personnel, protocol implementation process
and outcomes, changes in the study environment that
could affect collection efforts, and other factors directly
related to retention. Such factors may include flexible
staffing hours, recommended by some to insure that the
research interviews are convenient for the participant [34]
and home visits, although time consuming and costly,
that may have a positive impact on retention [21]. Quali-
tative research to better understand the range of interac-
tions between subject and researcher may also be useful in
developing testable hypotheses.
In conclusion, poor longitudinal visit participation is one
of the major challenges to study validity. Our data have
confirmed previous findings and suggested new insights.
We recommend that future longitudinal studies incorpo-
rate specific measures of participant attrition and reten-
tion into their design, including qualitative analysis of
participant-researcher interactions. In this way, real
progress may be made in understanding and improving
participation in studies.
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